Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092388 | 0.83 | DYRK1A (0.37) | DYRK1ACA1CA9KDM4ELMNA | |
| SCHEMBL4477930 | 0.75 | CDK9 (0.41) | DYRK1A | |
| SCHEMBL11669055 | 0.75 | — | — | |
| SCHEMBL3929855 | 0.75 | — | — | |
| SCHEMBL3487789 | 0.75 | — | — | |
| SCHEMBL4473650 | 0.75 | CA2 (0.32) | — | |
| SCHEMBL4151171 | 0.75 | ALDH1A1 (0.34) | MAPT | |
| SCHEMBL6869618 | 0.72 | AKR1B1 (0.48) | CA9KDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL15515840 | 0.72 | CYP2A6 (0.58) | — | |
| SCHEMBL7108442 | 0.72 | CYP2D6 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | claimed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-2951179-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | claimed |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | claimed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | claimed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | claimed |
| EP-1458393-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | claimed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | claimed |
| WO-2003053443-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | claimed |
| US-5843997-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | claimed |
| US-5576323-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | claimed |
| EP-0658539-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | DYRK1A 3197/4885CA1 4812/4885CA9 4386/4885 |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | DYRK1A 2442/4885CA1 3544/4885CA9 4771/4885 |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | DYRK1A 1247/4885CA1 3543/4885CA9 4715/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | DYRK1A 3197/4885CA1 4812/4885CA9 4386/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | DYRK1A 641/4885CA1 4877/4885CA9 4629/4885 |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | DYRK1A 822/4885CA1 3463/4885CA9 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.